Member Info for Brighty1

Yes, another excellent presentation. Very encouraging about the 200+ wells messaging plus we look to be on for dividends next year. We just need to keep the big boys from taking us over. £2 incoming in the next couple of months is my anticipation. Good luck, Brighty

Yes, hopefully the GSK new will help investors see that it's not all about Pfizer, AZ, Moderna etc and that there is potential for others in this space with the right treatment. i.e. SG016 / SNG001.
Good luck, Brighty

Things are hotting up in the Covid space as per GSK's RNS today: "Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that an Independent Data Monitoring Committee (IDMC) recommended that the Phase 3 COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) trial evaluating VIR-7831 (GSK4182136) as monotherapy for the early treatment of COVID-19 in adults at high risk of hospitalisation be stopped for enrolment due to evidence of profound efficacy".
Hopefully this will help investors see that it's not all about Pfizer, AZ, Moderna etc and that there is potential for others in this space with the right treatment. i.e. Sareum's SDC-1801.
Good luck, Brighty

Keep this research coming Citizen. It is excellent. Along with many posters on here you really do get the potential of SAR. Very interesting reading. Thank you. Good luck, Brighty

Yes, 60p incoming and then £1 by the end of 2021 (& probably £2 within 18 months at least). Good luck, Brighty

TYM RNS today: "pleased to be reporting solid progress at the Pyramid Project with widespread gold and silver mineralisation now being confirmed at surface within a number of long and persistent soil anomalies". Looking very encouraging. Good luck, Brighty

Here is the interesting bit from the RNS: "Tullow has now received approval for a new debt capacity amount under the Reserve Based Lending facility ("RBL") of $1.7 billion. With this new debt capacity agreed, Tullow has liquidity headroom and free cash of c.$0.9 billion. The combination of strong business delivery, increased liquidity, recent asset sales and higher commodity prices is providing a positive impetus to constructive discussions with creditors. The Group is confident that a mutually satisfactory agreement on debt refinancing can be reached in the first half of this year".
Fantastic. Good luck, Brighty

This is of particular interest in the ABDX Rns today re the consortia (of which we have 25% of the pie). "The Company is making good progress in the approval of AbC-19™ for testing in the US as well as with over 30 other countries worldwide. The Company has identified customers in seven countries that are being prioritised internally as Tier 1 commercial targets where, following registration of AbC-19™, the Company anticipates significant sizeable orders"...
Very encouraging. Good luck, Brighty

Just a general point Potnak, that's all, Stephen Parker has had plenty of opportunities to demonstrate his confidence in Sareum over the years with director buys but he's not really put his hand in his pocket like many of us on here have! I'm sure you are right and it's because we are in a closed period. Pivotal next few months. Fingers crossed. Good luck, Brighty

It would be nice to think that our chairman would be buying shares in Sareum - as he has done this week with another of his NED roles (MGC).
Name of Director Stephen Barry Parker Number acquired 282,316 £9,999.99
Good luck, Brighty

I invested in TEK two years ago - at under 10p - with a 5 year exit plan of 250p. This was based on TEK's strategy of creating value from breakthrough Uni tech. It is clear that their portfolio of Guident, Salarius, Lucyd and Belluscura all have massive potential. For those that have a long term investment plan this has huge promise as the RNS today highlights. Another 3 years and this could be 10 or 15 times higher, at least. Good luck, Brighty

A totally brilliant day for TEK investors. We own approximately 17.8% (10.5m shares) of Belluscura rising up to over 17 million as per the RNS with various warrants etc. This is a transformative development for TEK with Belluscura confirming that it is considering an IPO on AIM following the news that Belluscura plc has been granted 510(k) clearance and marketing authorisation by the U.S. Food and Drug Administration (FDA) for the X-PLO2R POC portable oxygen concentrator (POC).

"The X-PLO2R POC can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week. Weighing less than 3.25 lbs. (1.5 kg), the lightweight X-PLO2R POC is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as the Chronic Obstructive Pulmonary Disease (COPD) and respiratory distress caused by COVID-19. The X-PLO2R is expected to be commercially launched in 2021".

It's been worth the wait. Good luck, Brighty

50p milestone now achieved. Brilliant. Next milestone 65p and then £1+ by year end looks more than likely. We could even be looking at £1.50 by then. Good luck, Brighty

You might also want to try CNN's Richard Quest, who is a Brit in New York who broadcasts business stories each weekday evening between 8 and 9pm. FYI he's had Covid and reports regularly on pharma co's searching for a Covid cure Tweets @richardquest @questcnn As he is based in the USA he will be up to speed on Biden's mask wearing messaging. There's also Fergus Walsh at BBC News who is all over these kind of Covid stories. Plus SKY News’ science editor Thomas Moore reporting daily on Covid & ITN’s Emily Morgan (health) and Tom Clarke (science) are on most nights with Mary Nightingale and Tom Bradby talking about Covid developments. The Times / Sunday Times science reporter Sabah Meddings might be interested. Also, Katrina Turrill the Health Editor at The Express covers Covid stories most days plus Mary Kekatos is the senior health reporter at the Daily Mail online who covers Covid. Hope these names are of use to you. Good luck, Brighty.

Looking at the small print of the RNS the following sentence was very encouraging regarding the potential exclusive sales via Amazon... "ordering a minimum of 1 million masks per month". These are big numbers. Good luck, Brighty

Yes agreed, 50p soon and £1+ by year end looks more than likely. Good luck, Brighty

Just a heads up for those expecting an RNS with hard and fast revenue numbers attached to a Government contract win. It is worth noting that when NCYT announced its contract win with the UK Department of Health and Social Care (pasted below for clarity) it didn't include revenue, just details of the order volume in units (288,000 tests per week). i.e. We might not get financial numbers in a forthcoming DHSC contract RNS but we should get an idea of units contracted. e.g. we know 2 million a week is the optimum, according to the ODX 11th February RNS announcing the UK Government contract.

I was invested in NCYT at the time - and I still am - and would add that a further DHSC contract was awarded to NCYT and announced via RNS in September, this time including revenue. Both RNS' were received very well by the market and, as we know, resulted in significant share price rises.

I am anticipating a contract to be RNS'd by ODX perhaps without financial numbers but with a unit ratification of how many per week / per month and for ODX to then confirm the financial value at a later date via a trading update / interims / full year results etc. If this happened it would be in keeping with the DHSC NCYT initial announcement last April. Obviously, if ODX can confirm actual financial numbers all the better.

Exciting times for ODX and its share holders. Good luck, Brighty

"Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces it has signed a supply contract with the UK Department of Health and Social Care (DHSC) for its COVID-19 (CE IVD) polymerase chain reaction (PCR) test, developed by Primerdesign, the Company's molecular diagnostics division based in the UK.
Under the terms of the agreement, Novacyt will supply its COVID-19 test to the DHSC for an initial term of six months, starting from 4 May 2020. Novacyt has initially committed to supply 288,000 tests per week to the DHSC for use in the NHS, with the option to expand the agreement".

98p paid today. £1 incoming. £2 by the end of 2021. Good luck, Brighty

The Clinigen and Synairgen managed access programme for our IFN-beta SNG001 looks to have been another very astute move by Richard Marsden and the team at SNG. If what is being reported by the French health minister is correct and that the French are using it or about to use it for the treatment of hospitalised COVID-19 patients this is going to be massive news both commercially and in the fight against Covid. The Numis valuation could look very cheap. Bring on £9 a share! Good luck all SNG investors, Brighty

269p a share by December 31st this year for Barclays is what I reckon. Good luck, Brighty